Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
H.O. Conn.
Assessment of mental state.
The hepatic coma syndromes and lactulose, pp. 169-188
[2.]
S. Sen, R. Williams, R. Jalan.
The pathophysiology basis of acute-on-chronic liver failure.
Liver, 22 (2002), pp. 5-13
[3.]
L. Ruiz del Árbol, J. Urman, J. Fernández.
Systemic, renal and hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.
Hepatology, 38 (2003), pp. 1210-1218
[4.]
Demetriou A, Brown R, Busuttil RW, Fair J, McGuire B, Rosenthal P, et al. Prospective, randomized, multi-center, controlled trial of the HepatAssist system in treating acute liver failure [in press]. Ann Surg, 2004.
[5.]
P. Ferenci, A. Lockwood, K. Mullen, R. Tartar, K. Weissenborn, A.T. Blei.
Hepatic encephalopathy –definition, nomenclature, diagnosis, and quantification.
Hepatology, 35 (2002), pp. 716-721
[6.]
K. Gyr, R. Meier, J. Haussler, P. Bouletreau, W.E. Fleig, A. Holstege, et al.
Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomized, placebo controlled multicentre study.
Gut, 39 (1996), pp. 319-324
[7.]
R. Jalan, S. Sen, C. Steiner, D. Kapoor, A. Alisa, R. Williams.
Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe alcoholic hepatitis.
J Hepatol, 38 (2003), pp. 24-31
[8.]
G. Novelli, M. Rossi, R. Pretagostini, L. Poli, L. Novelli, P. Berloco, et al.
MARS experience in 34 cases of acute liver failure.
Liver, 22 (2002), pp. 43-47
[9.]
L.L. Kjaergard, J. Liu, B. Als-Nielsen, C. Gluud.
Artficial and bioartificial support systems for acute and acute-on-chronic failure: a systematic review.
JAMA, 289 (2003), pp. 217-222
[10.]
U. Heeman, U. Treichel, J. Loock, T. Philipp, G. Gerken, M. Malago, et al.
Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.
Hepatology, 36 (2002), pp. 949-958
[11.]
C.L. Fraser, A.I. Arieff.
Metabolic encephalopathy as a complication of renal failure: mechanisms and mediators.
New Horiz, 2 (1994), pp. 518-526
[12.]
F.V. Schiodt, J.O. Clemmesen, B.A. Hansen, F.S. Larsen.
Cerebral edema due to hemodialysis in paracetamol-induced fulminant hepatic failure.
Scand J Gastroenterol, 30 (1995), pp. 927-928
[13.]
R.F. Butterworth.
Molecular neurobiology of acute liver failure.
Semin Liver Dis, 23 (2003), pp. 251-258
[14.]
J. Vaquero, C. Chung, M. Cahill, A.T. Blei.
Pathogenesis of hepatic encephalopathy in acute liver failure.
Semin Liver Dis, 23 (2003), pp. 259-269
[15.]
J. Córdoba, A.T. Blei, S. Mujais.
Determinants of ammonia clearance by hemodialysis.
Artif Organs, 20 (1996), pp. 800-803
[16.]
S. Mitzner, J. Loock, P. Peszynski, S. Klammt, J. Majcher-Peszynska, A. Gramowski.
Metab Brain Dis, 17 (2002), pp. 463-475
[17.]
C. Yurdaydin, H. Hortnagl, P. Steindl, C. Zimmermann, C. Pifl, E.A. Singer.
Increased serotoninergic and noradrenergic activity in hepatic encephalopaty in rats with thioacetamide-induced acute liber failure.
Hepatology, 12 (1990), pp. 695-700
[18.]
J. Vorobioff, G. García-Tsao, R. Groszmann, G. Aceves, E. Picabea, Villavicencio, et al.
Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients.
Hepatology, 9 (1989), pp. 88-91
[19.]
P.E. Steindl, B. Finn, B. Bendok, S. Rothke, P.C. Zee, A.T. Blei.
Disruption of the diurnal rhythm of plasma melatonin in cirrhosis.
Ann Intern Med, 15 (1995), pp. 274-277
[20.]
C. Rose, R.F. Butterworth, J. Zayed, L. Normandin, K. Todd, A. Michalak, et al.
Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction.
Gastroenterology, 117 (1999), pp. 640-644
[21.]
S. Sen, M. Felldin, C. Steiner, B. Larson, G.T. Gillett, M. Olausson, et al.
Albumin dialysis and molecular adsorbents recirculating system (MARS) for acute Wilson’s disease.
Liver Transpl, 8 (2002), pp. 962-967
[22.]
E.A. Jones, A.S. Basile.
Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?.
Metab Brain Dis, 13 (1998), pp. 351-360
[23.]
C. Goulenok, B. Bernard, J.F. Cardranel, D. Thabut, V. Di Martino, P. Opolon, et al.
Flumazenil versus placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis.
Aliment Pharmacol Ther, 16 (2002), pp. 361-372
[24.]
A.T. Blei.
Infection, inflammation and hepatic encephalopathy, synergism redefined.
J Hepatol, 40 (2004), pp. 327-330
[25.]
S.S. Awad, S. Sawada, O.S. Soldes, P.B. Rich, R. Klein, W.H. Alarcon, et al.
Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system?.
ASAIO J, 45 (1999), pp. 47-49
[26.]
M. Guevara, C. Bru, P. Ginès, G. Fernández-Esparrach, P. Sort, R. Bataller, et al.
Increased cerebrovascular resistance in cirrhotic patients with ascites.
Hepatology, 28 (1998), pp. 39-44
[27.]
L.E. Schmidt, L.P. Wang, B.A. Hansen, F.S. Larsen.
Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial.
Liver Transpl, 9 (2003), pp. 290-297
[28.]
L.E. Schmidt, L.B. Svendsen, V.R. Sorensen, B.A. Hansen, F.S. Larsen.
Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure.
Liver Transpl, 7 (2001), pp. 709-712
[29.]
P.S. Kamath.
Is there life in MARS?.
Hepatology, 36 (2002), pp. 1017-1019
Supported by a Merit Review from the Veterans Administration Research Service and the Stephen B Tips Memorial Fund at Northwestern Memorial Hospital. Dr. Blei has received research funds from Teraklin, Inc, for the performance of a clinical trial of MARS.
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
